Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

Ross B Mounsey, Sarah Mustafa, Lianne Robinson, Ruth A. Ross, Gernot Riedel, Roger G. Pertwee, Peter Teismann*

*Corresponding author for this work

Research output: Contribution to journalArticle

23 Citations (Scopus)
4 Downloads (Pure)

Abstract

Parkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin. Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are available but no treatment slows or prevents the loss of neurons. Neuroinflammation has been implicated in its pathogenesis. To this end, the present study utilises the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to reproduce the pattern of cell death evident in PD patients. Herein, the role of a potential regulator of an immune response, the endocannabinoid system (ECS), is investigated. The most prevalent endocannabinoid, 2-arachidonoylglycerol (2-AG) (3 and 5 mg/kg), was added exogenously and its enzymatic degradation inhibited to provide protection against MPTP-induced cell death. Furthermore, the addition of DFU (25 mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects. Levels of 2-AG were shown to be upregulated in a time- and region-specific manner following MPTP administration, indicating that the ECS represents a natural defence mechanism against inflammation, potentiation of which could provide therapeutic benefits. The results expand the current understanding of the role that this signalling system has and its potential influence in PD.
Original languageEnglish
Pages (from-to)36-44
Number of pages9
JournalExperimental Neurology
Volume273
Early online date2 Aug 2015
DOIs
Publication statusPublished - Nov 2015

Keywords

  • Endocannabinoids
  • Parkinson's disease
  • MPTP
  • Neuroprotection
  • CB1 cannabinoid receptors
  • toxicity in-vivo
  • monoacylglycerol lipase
  • Huntingtons-Disease
  • cerebrospinal-fluid
  • Alzheimers-Disease
  • induced neurotoxicity
  • up-regulation
  • factor-alpha
  • brain

Cite this

Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. / Mounsey, Ross B; Mustafa, Sarah; Robinson, Lianne; Ross, Ruth A.; Riedel, Gernot; Pertwee, Roger G.; Teismann, Peter.

In: Experimental Neurology, Vol. 273, 11.2015, p. 36-44.

Research output: Contribution to journalArticle

@article{b32ff2040cb4492697d265ac5336bd97,
title = "Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease",
abstract = "Parkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin. Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are available but no treatment slows or prevents the loss of neurons. Neuroinflammation has been implicated in its pathogenesis. To this end, the present study utilises the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to reproduce the pattern of cell death evident in PD patients. Herein, the role of a potential regulator of an immune response, the endocannabinoid system (ECS), is investigated. The most prevalent endocannabinoid, 2-arachidonoylglycerol (2-AG) (3 and 5 mg/kg), was added exogenously and its enzymatic degradation inhibited to provide protection against MPTP-induced cell death. Furthermore, the addition of DFU (25 mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects. Levels of 2-AG were shown to be upregulated in a time- and region-specific manner following MPTP administration, indicating that the ECS represents a natural defence mechanism against inflammation, potentiation of which could provide therapeutic benefits. The results expand the current understanding of the role that this signalling system has and its potential influence in PD.",
keywords = "Endocannabinoids, Parkinson's disease, MPTP, Neuroprotection, CB1 cannabinoid receptors, toxicity in-vivo, monoacylglycerol lipase, Huntingtons-Disease, cerebrospinal-fluid, Alzheimers-Disease, induced neurotoxicity, up-regulation, factor-alpha, brain",
author = "Mounsey, {Ross B} and Sarah Mustafa and Lianne Robinson and Ross, {Ruth A.} and Gernot Riedel and Pertwee, {Roger G.} and Peter Teismann",
note = "Date of Acceptance: 28/07/2015 The authors are grateful to the staff of the Medical Research Facility for their help with the animal care. This work was supported by the NHS Endowment fund 09/03 and the Wellcome Trust (WT080782MF). We thank Merck & Co. Inc., Rathway NJ, USA for the supply of DFU.",
year = "2015",
month = "11",
doi = "10.1016/j.expneurol.2015.07.024",
language = "English",
volume = "273",
pages = "36--44",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "ACADEMIC PRESS INC ELSEVIER SCIENCE",

}

TY - JOUR

T1 - Increasing levels of the endocannabinoid 2-AG is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease

AU - Mounsey, Ross B

AU - Mustafa, Sarah

AU - Robinson, Lianne

AU - Ross, Ruth A.

AU - Riedel, Gernot

AU - Pertwee, Roger G.

AU - Teismann, Peter

N1 - Date of Acceptance: 28/07/2015 The authors are grateful to the staff of the Medical Research Facility for their help with the animal care. This work was supported by the NHS Endowment fund 09/03 and the Wellcome Trust (WT080782MF). We thank Merck & Co. Inc., Rathway NJ, USA for the supply of DFU.

PY - 2015/11

Y1 - 2015/11

N2 - Parkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin. Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are available but no treatment slows or prevents the loss of neurons. Neuroinflammation has been implicated in its pathogenesis. To this end, the present study utilises the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to reproduce the pattern of cell death evident in PD patients. Herein, the role of a potential regulator of an immune response, the endocannabinoid system (ECS), is investigated. The most prevalent endocannabinoid, 2-arachidonoylglycerol (2-AG) (3 and 5 mg/kg), was added exogenously and its enzymatic degradation inhibited to provide protection against MPTP-induced cell death. Furthermore, the addition of DFU (25 mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects. Levels of 2-AG were shown to be upregulated in a time- and region-specific manner following MPTP administration, indicating that the ECS represents a natural defence mechanism against inflammation, potentiation of which could provide therapeutic benefits. The results expand the current understanding of the role that this signalling system has and its potential influence in PD.

AB - Parkinson's disease (PD) is a common chronic neurodegenerative disorder, usually of idiopathic origin. Symptoms including tremor, bradykinesia, rigidity and postural instability are caused by the progressive loss of dopaminergic neurons in the nigrostriatal region of the brain. Symptomatic therapies are available but no treatment slows or prevents the loss of neurons. Neuroinflammation has been implicated in its pathogenesis. To this end, the present study utilises the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to reproduce the pattern of cell death evident in PD patients. Herein, the role of a potential regulator of an immune response, the endocannabinoid system (ECS), is investigated. The most prevalent endocannabinoid, 2-arachidonoylglycerol (2-AG) (3 and 5 mg/kg), was added exogenously and its enzymatic degradation inhibited to provide protection against MPTP-induced cell death. Furthermore, the addition of DFU (25 mg/kg), a selective inhibitor of inflammatory mediator cyclooxygenase-2 (COX-2), potentiated these effects. Levels of 2-AG were shown to be upregulated in a time- and region-specific manner following MPTP administration, indicating that the ECS represents a natural defence mechanism against inflammation, potentiation of which could provide therapeutic benefits. The results expand the current understanding of the role that this signalling system has and its potential influence in PD.

KW - Endocannabinoids

KW - Parkinson's disease

KW - MPTP

KW - Neuroprotection

KW - CB1 cannabinoid receptors

KW - toxicity in-vivo

KW - monoacylglycerol lipase

KW - Huntingtons-Disease

KW - cerebrospinal-fluid

KW - Alzheimers-Disease

KW - induced neurotoxicity

KW - up-regulation

KW - factor-alpha

KW - brain

U2 - 10.1016/j.expneurol.2015.07.024

DO - 10.1016/j.expneurol.2015.07.024

M3 - Article

VL - 273

SP - 36

EP - 44

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

ER -